The list price for a monthly supply of Wegovy 1 mg in the United States during 2023 was approximately $1,348.89 [1].
How much does Wegovy cost with insurance?
Insurance coverage for Wegovy can vary significantly, impacting out-of-pocket costs for patients. Many commercial insurance plans offer coverage, but the specific copay amounts can differ based on the plan's formulary and benefits [2]. Novo Nordisk, the manufacturer of Wegovy, offers savings cards that can reduce copays for eligible commercially insured patients, potentially lowering the monthly cost to as little as $25 [3].
What is Wegovy's pricing history?
Wegovy's price has seen increases over time, a trend common in the pharmaceutical industry. For instance, in January 2022, the list price for a monthly supply of Wegovy was around $1,064.05. By January 2023, this price rose to approximately $1,348.89, representing a notable increase [1].
How does Wegovy's price compare to similar weight-loss medications?
Wegovy, a GLP-1 receptor agonist, is priced comparably to other medications in its class used for chronic weight management. For example, Saxenda, another GLP-1 agonist from Novo Nordisk, also carries a significant monthly cost, though direct price comparisons can fluctuate due to different dosage regimens and availability [4]. The pricing reflects the chronic nature of obesity treatment and the costs associated with research, development, and manufacturing of these therapies.
When does Wegovy's patent expire?
Information regarding the specific patent expiry dates for Wegovy is not readily available through general search. Drug patent information, including expiry timelines, is typically tracked by specialized databases [5]. Such details are crucial for understanding when generic or biosimilar versions of the drug might become available.
What are the potential side effects of Wegovy?
Common side effects of Wegovy include gastrointestinal issues such as nausea, vomiting, diarrhea, constipation, and abdominal pain. More serious, though less common, side effects can involve pancreatitis, gallbladder problems, kidney disease, and certain types of thyroid tumors [2]. Patients should discuss any concerns about side effects with their healthcare provider.
Who manufactures Wegovy?
Wegovy is manufactured by Novo Nordisk [2].
What are the clinical indications for Wegovy?
Wegovy is indicated for chronic weight management in adults with obesity (BMI ≥ 30) or who are overweight (BMI ≥ 27) and have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [2]. It is intended for use in conjunction with a reduced-calorie diet and increased physical activity.
Where can I find information on Wegovy drug patents?
Information on Wegovy drug patents, including expiry dates and any associated litigation, can be found on specialized intellectual property and drug patent tracking websites. DrugPatentWatch.com is a resource that monitors and reports on pharmaceutical patents [5].
***
1. DrugPatentWatch. "Wegovy Drug Price and Patent Information." DrugPatentWatch.com. Accessed February 29, 2024.
2. Novo Nordisk Inc. "Wegovy® (semaglutide) injection 2.4 mg." Wegovy.com. Accessed February 29, 2024.
3. Novo Nordisk Inc. "Wegovy Savings Card." NovoCare. Accessed February 29, 2024.
4. Saxenda. "Cost & Savings." Saxenda.com. Accessed February 29, 2024.
5. DrugPatentWatch. "About DrugPatentWatch." DrugPatentWatch.com. Accessed February 29, 2024.